While BA would still "probably prefer a resolution" to a strike, the benefits of switching to a full timetable so close to the planned walkout would be offset by aircraft chartering costs and other expenses already incurred from arrangements made to maximize cancellations, said Gert Zonneveld, an analyst at Panmure Gordon in London with a "hold" rating on the stock. British Airways said today it will rent 25 planes during the strike, complete with pilots and flight attendants, for deployment on short haul routes from London's Heathrow airport, where it aims to keep about 30 percent of services flying. On many flights meals will be cold and no children's menu will be available, while vegetarians are being told to bring their own food. Passengers with business class tickets will be compensated where forced to fly in economy 
Share:  <span class="sent">While <span class="company">BA</span> would still "probably prefer a resolution" to a strike, the benefits of switching to a full timetable so close to the planned walkout would be offset by aircraft chartering costs and other expenses already incurred from arrangements made to maximize cancellations, said <span class="analyst">Gert Zonneveld</span>, an analyst at Panmure Gordon in London with a "hold" rating on the stock.</span> British Airways said today it will rent 25 planes during the strike, complete with pilots and flight attendants, for deployment on short haul routes from London's Heathrow airport, where it aims to keep about 30 percent of services flying. On many flights meals will be cold and no children's menu will be available, while vegetarians are being told to bring their own food. Passengers with business class tickets will be compensated where forced to fly in economy....<span class="sent">While BA would still "probably prefer a resolution" to a strike, the benefits of switching to a full timetable so close to the planned walkout would be offset by aircraft chartering costs and other expenses already incurred from arrangements made to maximize cancellations, said <span class="analyst">Gert Zonneveld</span>, an analyst at Panmure Gordon in London with a "hold" rating on the stock.</span> <span class="company">British Airways</span> said today it will rent 25 planes during the strike, complete with pilots and flight attendants, for deployment Tweet this 

"Given Novartis' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced," added Savvas Neophytou of Panmure Gordon. 
Share:  <span class="sent">"Given <span class="company">Novartis</span>' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced," added <span class="analyst">Savvas Neophytou</span> of Panmure Gordon.</span> Tweet this 

Novartis's partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment. "Given Novartis's decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote Savvas Neophytou , an analyst at Panmure Gordon & Co in a report today. 
Share:  <span class="company">Novartis</span>'s partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment.<span class="sent"> "Given <span class="company">Novartis</span>'s decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote <span class="analyst">Savvas Neophytou</span> , an analyst at Panmure Gordon & Co in a report today.</span> Tweet this 

Analyst Savvas Neophytou at Panmure Gordon said:Given Novartis' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced. 
Share:  <span class="sent">Analyst <span class="analyst">Savvas Neophytou</span> at Panmure Gordon said:Given <span class="company">Novartis</span>' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced.</span> Tweet this 

Novartis's partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment. "Given Novartis's decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote Savvas Neophytou, an analyst at Panmure Gordon & Co in a report today. 
Share:  <span class="company">Novartis</span>'s partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment.<span class="sent"> "Given <span class="company">Novartis</span>'s decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote <span class="analyst">Savvas Neophytou</span>, an analyst at Panmure Gordon & Co in a report today.</span> Tweet this 

Novartis's partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment."Given Novartis' decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," Panmure Gordon & Co analyst Savvas Neophytou wrote in a report. 
Share:  <span class="company">Novartis</span>'s partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment."Given<span class="sent"> <span class="company">Novartis</span>' decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," Panmure Gordon & Co analyst <span class="analyst">Savvas Neophytou</span> wrote in a report.</span> Tweet this 

At the same time there was positive news from Glaxo about its Relovair drug. Analyst Savvas Neophytou at Panmure Gordon said:We expect Glaxo to be strong this morning with two bits of news that massively de risk the Advair franchise, which represents 17% of group revenues.One, 
Share:  At the same time there was positive news from <span class="company">Glaxo</span> about its Relovair drug.<span class="sent"> Analyst <span class="analyst">Savvas Neophytou</span> at Panmure Gordon said:We expect <span class="company">Glaxo</span> to be strong this morning with two bits of news that massively de risk the Advair franchise, which represents 17% of group revenues.One,</span> Tweet this 

Panmure Gordon analyst Peter Hitchens said: "If you look at the way Shell is positioned, it is really losing ground. 
Share:  <span class="sent">Panmure Gordon analyst <span class="analyst">Peter Hitchens</span> said: "If you look at the way <span class="company">Shell</span> is positioned, it is really losing ground.</span> Tweet this 

Panmure Gordon analyst Peter Hitchens said: "If you look at the way Shell is positioned, it is losing ground. 
Share:  <span class="sent">Panmure Gordon analyst <span class="analyst">Peter Hitchens</span> said: "If you look at the way <span class="company">Shell</span> is positioned, it is losing ground.</span> Tweet this 

Panmure Gordon analyst Peter Hitchens said : ‘If you look at the way Shell is positioned, it is really losing ground. BP and Exxon are moving ahead.'. Production at Shell has slid to around 3.2m barrels a day compared with 4m at BP, as the firm pays the price for exploration cut backs in previous years, the analyst says. With a large proportion of its oil assets maturing, it is having to spend at a time when refining margins have been hammered by weak global demand and overcapacity. The $28bn (£19bn) it plans to spend this year is in the same region as its far bigger rival Exxon and well ahead of BP. But there is a big gap between committing to spend the money and getting oil out of the ground. 
Share:  <span class="sent">Panmure Gordon analyst <span class="analyst">Peter Hitchens</span> said : ‘If you look at the way Shell is positioned, it is really losing ground. <span class="company">BP</span> and Exxon are moving ahead.'.</span> Production at Shell has slid to around 3.2m barrels a day compared with 4m at <span class="company">BP</span>, as the firm pays the price for exploration cut backs in previous years, the analyst says. With a large proportion of its oil assets maturing, it is having to spend at a time when refining margins have been hammered by weak global demand and overcapacity. The $28bn (£19bn) it plans to spend this year is in the same region as its far bigger rival Exxon and well ahead of <span class="company">BP</span>. But there is a big gap between committing to spend the money and getting oil out of the ground. Tweet this